Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

BACKGROUND: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. OBJECTIVES: An existing Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban and apixaban, each compared with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Mark Access Health Policy
Main Authors: Bowrin, Kevin, Briere, Jean-Baptiste, Levy, Pierre, Millier, Aurélie, Tardu, Jean, Toumi, Mondher
Formato: Artigo
Idioma:Inglês
Publicado em: Routledge 2020
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7482848/
https://ncbi.nlm.nih.gov/pubmed/32944199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2020.1782164
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados